公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
1997 | Salvage surgery for recurrent nasopharyngeal carcinoma | Hsu M.-M; JENG-YUH KO ; Sheen T.-S; Chang Y.-L. | Archives of Otolaryngology - Head and Neck Surgery | 63 | 50 | |
2014 | Skewed distribution of IL-7 receptor-a-expressing effector memory CD8 + T cells with distinct functional characteristics in oral squamous cell carcinoma | JANG-JAER LEE ; Yeh C.-Y.; Jung C.-J.; Chen C.-W.; Du M.-K.; Yu H.-M.; Yang C.-J.; Lin H.-Y.; Sun A.; JENG-YUH KO ; SHIH-JUNG CHENG ; Chang Y.-L.; JEAN-SAN CHIA | PLoS ONE | 5 | 5 | |
2017 | SMYD3 Promotes Homologous Recombination via Regulation of H3K4-mediated Gene Expression | Chang Y.-L.; Tseng S.-F.; Huang Y.-C.; Shen Z.-J.; Hsu P.-H.; Hsieh M.-H.; Yang C.-W.; Tognetti S.; Canal B.; Subirana L.; Wang C.-W.; Chen H.-T.; Lin C.-Y.; Posas F.; SHU-CHUN TENG | Scientific Reports | 19 | 19 | |
2019 | Targeted treatment of primary aldosteronism – The consensus of Taiwan Society of Aldosteronism | KUO-HOW HUANG ; Yu C.-C.; Hu Y.-H.; CHIN-CHEN CHANG ; CHIEH-KAI CHAN ; Shih-Cheng Liao ; Tsai Y.-C.; SHIH-CHIEH CHUEH ; VIN-CENT WU ; YEN-HUNG LIN ; Lin J.-H.; Wang W.-J.; Wu C.-H.; Er L.-K.; Chang C.-H.; Chang Y.-L.; YI-LWUN HO ; Chang H.-W.; LIAN-YU LIN ; Hu F.-C.; KAO-LANG LIU ; SHUO-MENG WANG ; CHING-CHU LU ; RUOH-FANG YEN ; KWAN-DUN WU ; TAIPAI, Taiwan Primary Aldosteronism Investigator | Journal of the Formosan Medical Association | 21 | 18 | |
2021 | White matter network disruption and cognitive correlates underlying impaired memory awareness in mild cognitive impairment | Chang Y.-L.; Chao R.-Y.; Hsu Y.-C.; TA-FU CHEN ; YU-LING CHANG | NeuroImage: Clinical | 8 | 8 | |
2020 | White matter pathways underlying Chinese semantic and phonological fluency in mild cognitive impairment | Chang Y.-L.; TA-FU CHEN ; YU-LING CHANG | Neuropsychologia | 5 | 4 | |
2005 | YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole] exhibits a novel antiproliferative effect and arrests the cell cycle in G 0-G1 in human hepatocellular carcinoma cells | Wang S.-W.; Pan S.-L.; JIH-HWA GUH ; Chen H.-L.; Huang D.-M.; Chang Y.-L.; Kuo S.-C.; Lee F.-Y.; Teng C.-M. | Journal of Pharmacology and Experimental Therapeutics | 47 | 47 | |
2005 | YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models | Pan S.-L.; JIH-HWA GUH ; Peng C.-Y.; Wang S.-W.; Chang Y.-L.; Cheng F.-C.; Chang J.-H.; Kuo S.-C.; Lee F.-Y.; Teng C.-M. | Journal of Pharmacology and Experimental Therapeutics | 55 | 53 | |
2006 | YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9 | Liu Y.-N.; Pan S.-L.; Peng C.-Y.; JIH-HWA GUH ; Huang D.-M.; Chang Y.-L.; Lin C.-H.; Pai H.-C.; Kuo S.-C.; Lee F.-Y.; Teng C.-M. | Journal of Pharmacology and Experimental Therapeutics | 39 | 33 | |
2005 | YC-1 suppresses constitutive nuclear factor-κB activation and induces apoptosis in human prostate cancer cells | Huang Y.-T.; Pan S.-L.; JIH-HWA GUH ; Chang Y.-L.; Lee F.-Y.; Kuo S.-C.; Teng C.-M. | Molecular Cancer Therapeutics | 45 | 43 |